Jpmorgan Chase & CO Bolt Biotherapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 914 shares of BOLT stock, worth $530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
914
Previous 840
8.81%
Holding current value
$530
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding BOLT
# of Institutions
33Shares Held
19.1MCall Options Held
0Put Options Held
0-
Tang Capital Management LLC San Diego, CA3.81MShares$2.21 Million0.21% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.52MShares$2.04 Million0.33% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.75MShares$1.6 Million0.17% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA1.89MShares$1.1 Million0.97% of portfolio
-
Nan Fung Group Holdings LTD Central, K31.17MShares$676,8320.74% of portfolio
About Bolt Biotherapeutics, Inc.
- Ticker BOLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,641,500
- Market Cap $21.8M
- Description
- Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...